Cushing Syndrome Pipeline Insight 2024, Featuring Key Players Corcept Therapeutics, Sparrow Pharmaceuticals, Crinetics Pharmaceuticals and Key Products Relacorilant, SPI 62 and CRN-04894
| HRSAX Fund | USD 16.73 0.70 4.02% |
Slightly above 61% of Rational Real's investor base is looking to short. The analysis of overall sentiment of trading Rational Real Strategies mutual fund suggests that many investors are alarmed at this time. Rational Real's investing sentiment can be driven by a variety of factors including economic data, Rational Real's earnings reports, geopolitical events, and overall market trends.
Rational |
Dublin, Dec. 06, 2024 -- The Cushing Syndrome - Pipeline Insight, 2024 drug pipelines has been added to ResearchAndMarkets.coms offering.This report provides comprehensive insights about 4 companies and 4 pipeline drugs in the Cushing Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further hig
Read at finance.yahoo.com
 |
Rational Real Fundamental Analysis
We analyze Rational Real's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rational Real using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rational Real based on its fundamental data. In general, a quantitative approach, as applied to this mutual fund, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Position Weight
Cash Position Weight Comparative Analysis
Rational Real is one of the top funds in cash position weight among similar funds. Percentage of fund asset invested in cash equivalents or risk-free instruments. About 40% of all global funds carry cash on their balance sheet.
Rational Real Strategies Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Rational Real mutual fund to make a market-neutral strategy. Peer analysis of Rational Real could also be used in its relative valuation, which is a method of valuing Rational Real by comparing valuation metrics with similar companies.
Peers
Rational Real Related Equities
| RHSAX | Rational Strategic | 1.05 | ||||
| RDMCX | Rational Dynamic | 0.34 | ||||
| RDMIX | Rational Dynamic | 0.32 | ||||
| RDMAX | Rational Dynamic | 0.32 | ||||
| RFXIX | Rational Special | 0.06 | ||||
| RFXAX | Rational Special | 0.06 | ||||
| RFXCX | Rational Special | 0.06 | ||||
| HRSFX | Rational Real | 3.36 | ||||
| HRSAX | Rational Real | 4.02 |
Other Information on Investing in Rational Mutual Fund
Rational Real financial ratios help investors to determine whether Rational Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Rational with respect to the benefits of owning Rational Real security.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |